* Please refer to local prescribing information. Not all patients are candidates for 1x weekly dosing. In non-EU countries other FVIII treatments may have previously launched – or are currently available – which also offer 1x weekly dosing.
† Based on head-to-head studies comparing the pharmacokinetic profiles of Jivi vs. rFVIII-Fc and Jivi vs. rurioctocog alfa pegol
‡ At extension completion, patients received Jivi for a median (range) total time of 3.9 (0.8–7.0) years with 223 (23–698) exposure days